Atorvastatin hemicalcium
CAS No. 134523-03-8
Atorvastatin hemicalcium( Atorvastatin hemicalcium )
Catalog No. M11382 CAS No. 134523-03-8
A competitive inhibitor of HMG-CoA reductase (HMGCR) that acts as a lipid-lowering agent for prevention of events associated with cardiovascular disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
10MG | 41 | In Stock |
|
25MG | 48 | In Stock |
|
50MG | 55 | In Stock |
|
100MG | 91 | In Stock |
|
200MG | 149 | In Stock |
|
500MG | 281 | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAtorvastatin hemicalcium
-
NoteResearch use only, not for human use.
-
Brief DescriptionA competitive inhibitor of HMG-CoA reductase (HMGCR) that acts as a lipid-lowering agent for prevention of events associated with cardiovascular disease.
-
DescriptionA competitive inhibitor of HMG-CoA reductase (HMGCR) that acts as a lipid-lowering agent for prevention of events associated with cardiovascular disease.Dyslipidemia Approved(In Vitro):Atorvastatin treatment decreases apoptosis of myocardial cells by down-regulating GRP78, caspase-12 and CHOP expression in myocardial cells after myocardial infarction, and the endoplasmic reticulum (ER) stress is activated in response to heart failure and angiotensin II (Ang II) stimulation.(In Vivo):Atorvastatin (20-30 mg/kg; oral gavage; once a day; for 28 days; ApoE?/? mice) treatment significantly reduces endoplasmic reticulum (ER) stress signaling proteins, the number of apoptotic cells, and the activation of Caspase12 and Bax in the Ang II-induced ApoE-/- mice. Proinflammatory cytokines such as IL-6, IL-8, IL-1β are all remarkably inhibited after Atorvastatin treatment.
-
In VitroAtorvastatin treatment decreases apoptosis of myocardial cells by down-regulating GRP78, caspase-12 and CHOP expression in myocardial cells after myocardial infarction, and the endoplasmic reticulum (ER) stress is activated in response to heart failure and angiotensin II (Ang II) stimulation.
-
In VivoAtorvastatin (20-30 mg/kg; oral gavage; once a day; for 28 days; ApoE?/? mice) treatment significantly reduces endoplasmic reticulum (ER) stress signaling proteins, the number of apoptotic cells, and the activation of Caspase12 and Bax in the Ang II-induced ApoE-/- mice. Proinflammatory cytokines such as IL-6, IL-8, IL-1β are all remarkably inhibited after Atorvastatin treatment. Animal Model:Forty 8-week-old ApoE?/? mice induced with angiotensin II (Ang II) Dosage:20 mg/kg, 30 mg/kg Administration:Oral gavage; once a day; for 28 days Result:Significantly reduced ER stress signaling proteins, the number of apoptotic cells, and the activation of Caspase12 and Bax in the Ang II-induced ApoE?/? mice. Proinflammatory cytokines such as IL-6, IL-8, IL-1β were all remarkably inhibited
-
SynonymsAtorvastatin hemicalcium
-
PathwayMetabolic Enzyme/Protease
-
TargetHMGCR
-
RecptorHMG-CoAreductase
-
Research AreaCardiovascular Disease
-
IndicationDyslipidemia
Chemical Information
-
CAS Number134523-03-8
-
Formula Weight557.6324
-
Molecular FormulaC33H34FN2O5-
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4.CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4.[Ca+2]
-
Chemical Name1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (βR,δR)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Atorvastatin hemical...
A competitive inhibitor of HMG-CoA reductase (HMGCR) that acts as a lipid-lowering agent for prevention of events associated with cardiovascular disease.
-
Clinofibrate
Clinofibrate inhibits hydroxymethylglutaryl coenzyme A reductase (HMGCR) with IC50 of 0.47 mM.
-
Atorvastatin lactone
Atorvastatin lactone is a prodrug form of atorvastatin. Which is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.